Bilcare Limited has informed the Exchange about the approval of Unaudited Financial Results (Standalone and Consolidated) for the period ended 31.12.2025 along with Limited Review Report.

Bilcare Limited's board approved its unaudited Q3 FY26 results on February 12, 2026. On a consolidated basis, 9M FY26 revenue fell to Rs 545.88 crore from Rs 594.03 crore a year ago, while the net loss narrowed to Rs 45.89 crore from Rs 61.20 crore. Standalone results are small, with Q3 revenue of Rs 1.73 crore and PAT of Rs 2.71 crore. Two key corporate actions were announced: subsidiary Caprihans India Limited (CIL) will redeem 2.80 crore 0.1% preference shares held by Bilcare (out of 16.66 crore outstanding) by March 31, 2026, and Bilcare will convert 18.70 lakh warrants of CIL into equity shares by paying Rs 28.05 crore (balance 75%). The auditor (Patki & Soman) flagged a material going concern uncertainty due to past operating losses, questioned treating Rs 14.42 crore CSIR loan penal interest as a contingent liability rather than a provision, and noted the CSIR loan should have been classified as a current borrowing due to default. The previous quarter was reviewed by a different firm (Sharp & Tannan Associates), indicating an auditor change.